These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27587303)

  • 1. Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease.
    Reick C; Ellrichmann G; Tsai T; Lee DH; Wiese S; Gold R; Saft C; Linker RA
    Exp Neurol; 2016 Nov; 285(Pt A):12-23. PubMed ID: 27587303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms.
    Corey-Bloom J; Aikin AM; Gutierrez AM; Nadhem JS; Howell TL; Thomas EA
    Brain Res; 2017 Oct; 1673():102-110. PubMed ID: 28823953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant Huntingtin Impairs BDNF Release from Astrocytes by Disrupting Conversion of Rab3a-GTP into Rab3a-GDP.
    Hong Y; Zhao T; Li XJ; Li S
    J Neurosci; 2016 Aug; 36(34):8790-801. PubMed ID: 27559163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
    Corey-Bloom J; Jia H; Aikin AM; Thomas EA
    J Huntingtons Dis; 2014; 3(3):311-6. PubMed ID: 25300334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
    Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
    Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice.
    Zajac MS; Pang TY; Wong N; Weinrich B; Leang LS; Craig JM; Saffery R; Hannan AJ
    Hippocampus; 2010 May; 20(5):621-36. PubMed ID: 19499586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347.
    Conforti P; Ramos C; Apostol BL; Simmons DA; Nguyen HP; Riess O; Thompson LM; Zuccato C; Cattaneo E
    Mol Cell Neurosci; 2008 Sep; 39(1):1-7. PubMed ID: 18571429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BH3-only proteins Bid and Bim(EL) are differentially involved in neuronal dysfunction in mouse models of Huntington's disease.
    García-Martínez JM; Pérez-Navarro E; Xifró X; Canals JM; Díaz-Hernández M; Trioulier Y; Brouillet E; Lucas JJ; Alberch J
    J Neurosci Res; 2007 Sep; 85(12):2756-69. PubMed ID: 17387706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
    Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
    J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Astrocytes Promote Oligodendrogenesis after White Matter Damage via Brain-Derived Neurotrophic Factor.
    Miyamoto N; Maki T; Shindo A; Liang AC; Maeda M; Egawa N; Itoh K; Lo EK; Lok J; Ihara M; Arai K
    J Neurosci; 2015 Oct; 35(41):14002-8. PubMed ID: 26468200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease.
    Giampà C; Montagna E; Dato C; Melone MA; Bernardi G; Fusco FR
    PLoS One; 2013; 8(5):e64037. PubMed ID: 23700454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trehalose rescues glial cell dysfunction in striatal cultures from HD R6/1 mice at early postnatal development.
    Perucho J; Gómez A; Muñoz MP; de Yébenes JG; Mena MÁ; Casarejos MJ
    Mol Cell Neurosci; 2016 Jul; 74():128-45. PubMed ID: 27236019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
    Seo H; Kim W; Isacson O
    Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.
    Peng Q; Masuda N; Jiang M; Li Q; Zhao M; Ross CA; Duan W
    Exp Neurol; 2008 Mar; 210(1):154-63. PubMed ID: 18096160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy by proteasome activator, PA28γ, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.
    Jeon J; Kim W; Jang J; Isacson O; Seo H
    Neuroscience; 2016 Jun; 324():20-8. PubMed ID: 26944602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.
    Miguez A; García-Díaz Barriga G; Brito V; Straccia M; Giralt A; Ginés S; Canals JM; Alberch J
    Hum Mol Genet; 2015 Sep; 24(17):4958-70. PubMed ID: 26063761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease.
    Giralt A; Friedman HC; Caneda-Ferrón B; Urbán N; Moreno E; Rubio N; Blanco J; Peterson A; Canals JM; Alberch J
    Gene Ther; 2010 Oct; 17(10):1294-308. PubMed ID: 20463759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.